FDA 批准辉瑞-BioNTech 的 Omicron KP.2 疫苗用于对亚变体的免疫力。 FDA approves Pfizer-BioNTech's Omicron KP.2 vaccine for immunity against the subvariant.

美国食品和药物管理局批准了瑞-生物科技公司的Omicron KP.2 COVID-19疫苗,该疫苗旨在提供对Omicron亚型的免疫力. The FDA has granted approval for Pfizer-BioNTech's Omicron KP.2 COVID-19 vaccine, designed to provide immunity against the Omicron subvariant. 疫苗经过了严格的测试和评价,以确保其安全和有效保护个人免受KP.2菌株的影响。 The vaccine has undergone rigorous testing and evaluation to ensure its safety and efficacy in protecting individuals from the KP.2 strain. 预计其可用性将有助于遏制Omicron变异物及其子系列的传播。 Its availability is expected to help curb the spread of the Omicron variant and its sublineages.